Regimen for the Treatment of Cachexia in Subjects With NSCLC

Inclusion Criteria: * Subjects with NSCLC * Demonstrating average weight loss of 5% within 2 months prior to enrollment * Heart rate of 72 bpm or greater * Negative pregnancy test (female patients of child bearing age) * Able to give informed consent * Able to be administered medication * Able to take food and defined nutritional support * Have not been on beta-blockers for a minimum of 1 week prior to administration of the medication screening dose * Have not undergone surgery for at least 2 weeks prior to entry into trial * Have not been on chemotherapy, immunotherapy, biologic therapy, radio therapy, and experimental therapy for a minimum of two weeks prior to medication screening dose and during their participation in this trial * An expected survival for a minimum of 12 weeks Exclusion Criteria: * Contraindication to nonsteroidal antiinflammatory drugs (NSAIDs) and beta blockers * Blood pressure less than 100/65 * Weight loss of 15% within 2 months prior to recruitment * Hypersensitivity reaction to the active components in VT-122 * History of myocardial infraction within the past 3 months * Congestive heart failure (as determined by symptoms and ECG) * A-V block of second or third degree * Unstable angina * Uncontrolled diabetes * Unable to be assessed for grip strength * A positive pregnancy test * Chronic infection or sepsis * History of bleeding disorders * Patients with peripheral edema * Patients on digoxin or other chronotropic drugs * Patients with evidence of severe dehydration * Patients with evidence of ascites